BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kamarajah SK, Bundred JR, Boyle C, Oo J, Pandanaboyana S, Loveday B. Impact of neoadjuvant therapy on post-operative pancreatic fistula: a systematic review and meta-analysis. ANZ J Surg. 2020;90:2201-2210. [PMID: 32418344 DOI: 10.1111/ans.15885] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Zhou Y, Liao S, You J, Wu H. Conversion surgery for initially unresectable pancreatic ductal adenocarcinoma following induction therapy: a systematic review of the published literature. Updates Surg 2021. [PMID: 34021484 DOI: 10.1007/s13304-021-01089-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Garnier J, Robin F, Ewald J, Marchese U, Bergeat D, Boudjema K, Delpero JR, Sulpice L, Turrini O. Pancreatectomy with Vascular Resection After Neoadjuvant FOLFIRINOX: Who Survives More Than a Year After Surgery? Ann Surg Oncol 2021;28:4625-34. [PMID: 33462718 DOI: 10.1245/s10434-020-09520-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dhir M, Are C. Another Potential Benefit of Neoadjuvant Therapy in Pancreatic Cancer: Reduction in Postoperative Readmission Rates. Ann Surg Oncol 2021;28:1871-3. [PMID: 33389295 DOI: 10.1245/s10434-020-09474-7] [Reference Citation Analysis]
4 Rieser CJ, Zenati M, Narayanan S, Bahary N, Lee KK, Paniccia A, Bartlett DL, Zureikat AH. Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit? Ann Surg Oncol 2021. [PMID: 33748894 DOI: 10.1245/s10434-021-09822-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 van Dongen JC, Wismans LV, Suurmeijer JA, Besselink MG, de Wilde RF, Groot Koerkamp B, van Eijck CHJ. The effect of preoperative chemotherapy and chemoradiotherapy on pancreatic fistula and other surgical complications after pancreatic resection: a systematic review and meta-analysis of comparative studies. HPB (Oxford) 2021:S1365-182X(21)00143-X. [PMID: 34099372 DOI: 10.1016/j.hpb.2021.04.027] [Reference Citation Analysis]
6 Nappo G, Donisi G, Zerbi A. Borderline resectable pancreatic cancer: Certainties and controversies. World J Gastrointest Surg 2021; 13(6): 516-528 [PMID: 34194610 DOI: 10.4240/wjgs.v13.i6.516] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Kamarajah SK, Naffouje SA, Salti GI, Dahdaleh FS. Neoadjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma is Associated with Lower Post-Pancreatectomy Readmission Rates: A Population-Based Cohort Study. Ann Surg Oncol 2021;28:1896-905. [PMID: 33398644 DOI: 10.1245/s10434-020-09470-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]